Doctors Urge Residents to Get Flu Vaccine before Schools Begin

Taking a shot before the start of flu season in September

Dubai, United Arab Emirates-Sunday 1 September 2019 [ AETOS Wire ]

With flu season around the corner, and schools just about to begin, Emirates Hospital-Jumeirah is launching a campaign to emphasise the importance of getting the flu vaccine and taking all the necessary precautions to prevent the risk of getting sick and contracting life threatening illnesses due to the Influenza.

The campaign is scheduled to begin on September 1st and will provide vaccinations to patients of all age groups at AED 99 including consultation from healthcare providers at the hospital. Emirates Hospital - Jumeirah, a subsidiary of Emirates Healthcare Company, is an internationally recognised 100-bed beacon of progress in the region’s healthcare system. The company owns and operates an extensive portfolio of full-service hospitals, specialty clinics, urgent care centers, aesthetic and cosmetic clinics and pharmacies.

“Influenza vaccination or flu shot, is a seasonal vaccine that protects against Influenza A, B and their strains that causes severe flu infections. It is recommended to be taken annually, as every year it is updated to include the main viruses known to cause the flu,” said, Dr Yanal Salam, Specialist Internal Medicine, Emirates Hospital – Jumeirah.

Each year, the flu virus strikes any time between September to April and increases the probability of contracting several mild to chronic respiratory illnesses caused by different strains of the virus. The flu vaccine is known to lower the risk of getting affected by more than 50% which could otherwise cause severe complications. Complications are reported particularly among infants till 5 years of age, older population ie- 60 years and above and in high risk patients with medical conditions such as asthma, chronic lung diseases, heart disease, diabeties, chronic liver and kidney disorders, blood related disorders, neurological disorders, weak immunity and individuals with morbid obesity.

The vaccine makes the body immune towards contracting the flu usually within two weeks of administering the shot, and protects against Influenza A H1N1, Influenza B and H3N2. Getting the vaccine on time and taking the necessary precautions also helps prevent spreading in the community.

The side effects of the flu vaccine are reportedly mild and known to subside gradually. Patients usually complain of soreness, redness or swelling of the area where the shot was administered or low-grade fever and muscle pains. In adults the flu shot most often causes headache, muscle pain and fatigue. In either case the symptoms last for 1-2 days and does not require any treatment.

Some other factors to keep in mind to avoid getting infected include maintaining highest level of hygiene at all times, having foods rich in Vitamin C to build immunity, covering mouth while coughing or sneezing to prevent the spread of infection and visiting the doctor if experiencing fever, cough or chills.

Lastly, it is also important not to send the children to nursery or school when they are infected to prevent the spread across to others.

About Emirates Hospital - Jumeirah:

An Emirates Healthcare Company, Emirates Hospital - Jumeirah is an internationally recognised 100-bed beacon of progress in the region’s healthcare system. It provides personalised, real-time healthcare solutions, and its core values are Simplicity, Accessibility, Agility, and Empathy.

Located on Jumeirah Beach Road alongside the Dubai Canal, Emirates Hospital - Jumeirah is home to some of the world’s leading medical professionals, and it delivers the highest quality of healthcare.

Emirates Hospital - Jumeirah partners with regulators, institutions, insurers and manufacturers to develop and nurture new ideas and long-term strategies that create positive change in people’s homes and everyday lives. Emirates Hospital - Jumeirah is operated by NMC Health Plc; KBBO Group is the largest single shareholder of NMC.

Emirates Specialty Hospital in Dubai Healthcare City is an Emirates Healthcare Company. A 90-bed facility with superior technology and experienced, internationally-trained staff, Emirates Specialty Hospital delivers an unrivalled range of much-needed specialties.

Emirates Healthcare is a subsidiary of KBBO Group. A leading holding company headquartered in Abu Dhabi, KBBO Group invests in healthcare to safeguard the region’s communities, and to help deliver world-class medical outcomes powering an inclusive and improved quality of life.

Contacts

SAHARA Communications

Maria F. Tayem, Senior Account Manager, +971501714347, +97143298996

m.tayem@saharapr.com / www.saharagcc.com

Permalink : https://www.aetoswire.com/news/doctors-urge-residents-to-get-flu-vaccine-before-schools-begin/en

PTW International Announces the Launch of Esports Team- Orange Rock Esports

Pole To Win International announces its first foray into the Esports world with the launch of Orange Rock Esports 

SAN FRANCISCO-Friday 30 August 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Pole To Win International, Ltd. (PTW), the industry-leading video games and tech services outsourcer, today announced that it is launching a top-tier Esports team. The team is composed of former members from the Indian Tigers as well as other top pro players. The team is already one of the top three teams in India, qualified for the ESL championship in Milan and trending as the fan favorite in India.

 “The growth and potential of Esports is phenomenal,” said Deborah Kirkham, CEO of PTW. “Orange Rock Esports represents our first foray into an incredibly exciting arena. We are thrilled to join this rapidly growing industry and ready to cheer on our talented team.”

“It’s predicted that there will be 557 million Esports enthusiasts by 2021 and PTW is eager to play a role in capturing the hearts and minds of Esports viewers,” added Kasturi Rangan, President of PTW America and India. “At PTW, we are all gamers at heart, which makes this an extra exciting move for us. There was a recent PMCO event where the team attracted over 3.7 million viewers and was voted as the fan favorite by over 660,000 votes. Many of us have been fans of the Indian Tigers, and now we look forward to directly supporting the success of our team, PTW’s newly-formed Orange Rock Esports.”

The Orange Rock Esports team is currently undergoing an exclusive bootcamp in Hyderabad, India. They will be training together for the next two months under the management of Bharat Kiran Reddy (also known as Ribbi) who is a legend in the pro Esports community in India. Prevailing over 500 other teams playing in India, Orange Rock Esports will have its first chance to compete as a team in late September, having qualified for the Vodafone 5G PUBG Mobile finals in Milan, representing India.

“Now that we have spent time coalescing as a team, we are stronger than ever and ready to dominate the PUBG Mobile arena. We are so excited to be working with PTW to build the future of Esports as Orange Rock Esports,” said Bharat Kiran Reddy, Orange Rock’s team coach and spokesperson.

About Pole To Win International

Pole To Win International, Ltd. (PTW) is a leading games, digital entertainment and interactive media solutions provider with 16 offices in 10 countries worldwide. Our range of services include quality assurance, localization, customer experience, engineering and development services, and audio production services. PTW brings 25 years’ experience and the infrastructure to create customized support for projects and clients of all sizes.

PTW, comprised of global subsidiaries, is a UK-based holding company formed in 2016 under the umbrella of Poletowin Pitcrew Holdings, Inc. which is listed on the 1st Section of Tokyo Stock Exchange as 3657. POLE TO WIN is a registered trademark of Pole To Win Co., Ltd. in Japan and other countries. All rights reserved. For more information, visit https://www.ptw.com/

Stay connected with PTW on Facebook, Twitter and LinkedIn.

For queries related to Orange Rock Esports please email pr@orangerock.com

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190829005163/en/

---

Contacts

Allison DeLeo
Racepoint Global for Pole To Win International
Phone: +1 (415) 694-6700
ptw@racepointglobal.com

Permalink : https://www.aetoswire.com/news/ptw-international-announces-the-launch-of-esports-team-orange-rock-esports/en

توشيبا ميموري تستحوذ على أعمال محركات الأقراص ذات الحالة الصلبة التابعة لشركة لايت-أون تكنولوجي التايوانية

طوكيو-السبت 31 أغسطس 2019 [ ايتوس واير ]

(بزنيس واير): أعلنت اليوم شركة "توشيبا ميموري هولدينجز"، التي ستغيّر علامتها التجاريّة إلى "كيوكسيا هولدينجز" في الأوّل من أكتوبر 2019، أنّها وقّعت اتّفاقيّة نهائيّة مع شركة "لايت-أون تكنولوجي" للاستحواذ على أعمال محركات الأقراص ذات الحالة الصلبة ("إس إس دي") خاصّتها. يبلغ سعر الشراء 165 مليون دولار أمريكي؛ ويُتوقّع أن تُغلق الصفقة بحلول النصف الأوّل من عام 2020 وتخضع إلى تسويات الإغلاق والموافقات التنظيميّة المعتادة.

تُعدّ "لايت-أون" مزوّدة لأجهزة الإلكترونيّات البصريّة والتخزين وأشباه الموصّلات وأجهزة أخرى، تتخذ من تايوان مقرّاً لها. وتتشارك "توشيبا ميموري" و"لايت-أون" الالتزام بالامتياز على صعيد الجودة والابتكار والتصنيع. ومع التفاعل الثقافي والخبرة الموثوقة لشركة "لايت-أون" في مجال محركات الأقراص ذات الحالة الصلبة للحواسيب الشخصيّة ومراكز البيانات، تنظر "توشيبا ميموري" إلى هذا الاستحواذ كطريقة لتعزيز أعمالها لمحركات الأقراص ذات الحالة الصلبة بشكلٍ كبير.

وقال نوبو هاياساكا، الرئيس بالنيابة والرئيس التنفيذي لشركة "توشيبا ميموري هولدينجز"، في هذا السياق: "تتوافق أعمال محركات الأقراص ذات الحالة الصلبة من ’لايت-أون‘ بشكلٍ طبيعي واستراتيجي مع ’توشيبا ميموري‘ وتوسّع مدى تركيزنا على قطاع محركات الأقراص ذات الحالة الصلبة. ويعتبر هذا الاستحواذ مهمّ بالنسبة إلينا إذ يسمح لنا بتلبية النموّ المتوقّع في الطلبات على محركات الأقراص ذات الحالة الصلبة في الحواسيب ومراكز البيانات، وهو ما يحرّكه الاستخدام المتزايد لخدمات السحابة".

وتجدر الإشارة إلى أن "توشيبا ميموري" ستستفيد من الابتكارات الرائدة من شركة "لايت-أون" لتحسين موقعها الرائد في سوق محركات الأقراص ذات الحالة الصلبة.

لمحة عن شركة "لايت-أون تكنولوجي"

تأسست: عام 1975

المقرّ الرئيسي: تايبيه، تايوان

رئيس مجلس الإدارة: رايموند سونج

العائدات: إيرادات صافية بقيمة 207.1 مليار دولار أمريكي (العام المالي 2018)

لمحة عن "توشيبا ميموري"

تكرّس مجموعة "توشيبا ميموري"، الشركة الرائدة عالمياً في مجال حلول الذاكرة، جهودها لتطوير وإنتاج وبيع ذاكرة فلاش ومحركات الأقراص ذات الحالة الصلبة. في أبريل 2017، انفصلت شركة "توشيبا ميموري" عن "توشيبا كوربورايشن"، الشركة التي ابتكرت ذاكرة فلاش بتقنية "ناند" في عام 1987. وتعتبر "توشيبا ميموري" شركة رائدة في تقديم حلول الذاكرة والخدمات المتطورة التي تثري حياة الناس وتوسع آفاق المجتمع. وتقوم "بيكس فلاش"، وهي تقنية ذاكرة الفلاش ثلاثية الأبعاد المبتكرة الخاصة بالشركة، برسم معالم مستقبل التخزين في التطبيقات عالية الكثافة بما في ذلك الهواتف الذكية المتطورة، والحواسيب الشخصية، ومحركات الأقراص ذات الحالة الصلبة، والسيارات، ومراكز البيانات. وستقوم "توشيبا ميموري" رسمياً بتغيير اسمها إلى "كيوكسيا" في 1 أكتوبر 2019. للمزيد من المعلومات حول "توشيبا ميموري"، يرجى زيارة الرابط الإلكتروني التالي: https://business.toshiba-memory.com/en-jp/.

يمكنكم الاطلاع على النسخة الأصلية للبيان الصحفي على موقع "بزنيس واير" (businesswire.com) على الرابط الإلكتروني التالي: https://www.businesswire.com/news/home/20190830005147/en/

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

Contacts

للمزيد من المعلومات:

ساتوشي إيتو

ويبر شاندويك" (اليابان)

هاتف: +81(0)8010781657

البريد الإلكتروني: SIto@webershandwick.com

أو

العلاقات العامة وعلاقات المستثمرين

شركة "توشيبا ميموري هولدينجز"

البريد الإلكتروني: tmchq-tmchd-info@ml.toshiba.co.jp

الرابط الثابت : https://www.aetoswire.com/ar/news/توشيبا-ميموري-تستحوذ-على-أعمال-محركات-الأقراص-ذات-الحالة-الصلبة-التابعة-لشركة-لايت-أون-تكنولوجي-التايوانية/ar

Toshiba Memory to Acquire the SSD Business of Taiwan’s LITE-ON Technology

TOKYO-Saturday 31 August 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Toshiba Memory Holdings Corporation, which will rebrand as Kioxia Holdings Corporation on October 1, 2019, announced today that it has signed a definitive agreement with LITE-ON Technology Corporation to acquire its Solid State Drive (SSD) business. The purchase price is 165 million US dollars; the transaction is expected to close by the first half of 2020 and is subject to customary closing adjustments and regulatory approval.

LITE-ON is a Taiwan-based supplier of optoelectronics, storage, semiconductors and other devices. Toshiba Memory and LITE-ON share a commitment to quality, innovation and manufacturing excellence. With cultural synergies and LITE-ON’s proven experience in the SSD field for personal computers and data centers, Toshiba Memory sees this acquisition as a way to significantly strengthen its SSD business.

“LITE-ON’s Solid State Drive business is a natural and strategic fit with Toshiba Memory and expands our focus in the SSD industry,” said Nobuo Hayasaka, acting President and CEO of Toshiba Memory Holding Corporation. “This is an exciting acquisition for us, as it positions us to meet the projected growth in demand for SSDs in PCs and data centers being driven by the increased use of cloud services.”

Toshiba Memory will leverage LITE-ON’s leading innovations to enhance its leadership position in the SSD market.

About LITE-ON Technology Corporation

Founded: 1975
Headquarters: Taipei, Taiwan
Chairman: Raymond Soong
Revenues: NT$207.1 billion (FY2018)

About Toshiba Memory

Toshiba Memory Group, a world leader in memory solutions, is dedicated to the development, production and sale of flash memory and solid state drives (SSDs). In April 2017, Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Toshiba Memory pioneers cutting-edge memory solutions and services that enrich people's lives and expand society's horizons. The company's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers. Toshiba Memory will officially change its name to Kioxia on October 1, 2019. For more information on Toshiba Memory, please visit https://business.toshiba-memory.com/en-jp/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190830005147/en/

Contacts
For More Information
Satoshi Ito
Weber Shandwick Japan
Phone: +81 (0)80 1078 1657
Email: SIto@webershandwick.com

Public Relations & Investor Relations
Toshiba Memory Holdings Corporation
Email: tmchq-tmchd-info@ml.toshiba.co.jp

Permalink : https://www.aetoswire.com/news/toshiba-memory-to-acquire-the-ssd-business-of-taiwanrsquos-lite-on-technology/en

أندرسن جلوبال توسع عملياتها إلى الدولة الـ 15 في إفريقيا

سان فرانسيسكو-الجمعة 30 أغسطس 2019 [ ايتوس واير ]

(بزنيس واير): أعلنت اليوم "أندرسن جلوبال" عن إبرام اتفاقية تعاون مع "إيه تاكس أدفايزرز" المحدودة ("إيه تاكس")، وهي شركة رائدة في مجال الضرائب والاستشارات في موريشيوس- البلد الـ 15 في أفريقيا الذي تملك فيه المنظمة العالمية حضوراً الآن في خطوةٍ تشكّل محطةً بارزة في جهودها للتوسع في قارة أفريقيا.

وتتخذ "إيه تاكس" من دولة جزر الموريشيوس بشرق أفريقيا مقراً لها، وقدمت للعملاء مجموعة من الخدمات في مجال المحاسبة والضرائب والرواتب والتلزيم والاستشارات التجارية على مدى السنوات الـ15 الماضية. كما تلبي الشركة احتياجات العملاء الدوليين في جميع أنحاء العالم من خلال خبرة متخصصة موجّهة للعملاء الأفارقة والآسيويين، حيث تُعرف دولة موريشيوس بأنها البوابة إلى الهند وآسيا وكذلك أفريقيا.

ويتمتع بن ليم، أحد مؤسسي "إيه تاكس"، وفريقه بخبرة واسعة متخصصة في مجموعة واسعة من القطاعات، بما في ذلك الصناعات التحويلية وتصنيع المنسوجات والملابس، وبناء وتجديد العقارات، والصناعات الطبية والصيدلانية، وقطع غيار السيارات والمركبات الآلية، والزراعة والفلاحة، وتجارة الجملة والتجزئة في مجال السلع الاستهلاكية، والضيافة والسياحة، والتعليم، ومشاريع البناء والتشغيل ونقل الملكية "بي أو بيه"، والوساطة الجمركية، وشحن البضائع، والمجوهرات، والمراهنة، والمطاعم، والبيع بالتجزئة وإدارة الفعاليات. ويتمتع فريق موريشيوس بخبرة واسعة في التخطيط الضريبي العابر للحدود. كما أن "إيه تاكس" عضو في معهد موريشيوس للمحاسبين العموميين.

وقال بن في هذا السياق: "بذلنا الكثير من الوقت والجهد في صياغة مشروع تجاري يركز على تقديم الخدمات الأفضل في فئتها ومعاملة العملاء كما لو كانوا من أفراد عائلتنا. وبفضل هذه القيم والمساعي البسيطة، تمكنّا من تطوير مكانتنا وسمعتنا"، مضيفاً: "نتطلع إلى هذه الخطوة القادمة في مسيرة شركتنا وإلى التعاون مع مجموعة من الزملاء ذوي التفكير المشابه في جميع أنحاء العالم".

ومن جانبه، قال مارك فورساتز، رئيس مجلس إدارة "أندرسن جلوبال" والرئيس التنفيذي لشركة "أندرسن تاكس" المحدودة: "يشكل المتخصصون في شركة ’إيه تاكس‘ فريقاً متميزاً في موريشيوس، وهناك الكثير من الفرص المتاحة بفضل هذا التعاون. ويملك بن جذوراً في عائلة ’أندرسن‘؛ ولهذا السبب، فإن قيماً مثل الشفافية والسلاسة والإدارة الجيدة تبدو متأصلة". وأضاف: "يشهد زخمنا في هذه المنطقة نمواً، وسوف يكون لدينا الشريك الأفضل لترسيخ مكانتنا في هذا السوق المهم في إفريقيا".

وتُعتبر "أندرسن جلوبال" رابطة دولية من الشركات الأعضاء المستقلة والمنفصلة قانوناً، وتضمّ أخصائيين في الخدمات الضريبية والقانونية من جميع أنحاء العالم. تأسست الرابطة في العام 2013 من قبل الشركة العضو الأمريكية "أندرسن تاكس" المحدودة. وتضمّ "أندرسن جلوبال" حالياً أكثر من 4,500 أخصائي في جميع أنحاء العالم وتتمتع بحضور في أكثر من 148 موقعاً من خلال الشركات الأعضاء والشركات المتعاونة.

يمكنكم الاطلاع على النسخة الأصلية للبيان الصحفي على موقع "بزنيس واير" (businesswire.com) على الرابط الإلكتروني التالي: https://www.businesswire.com/news/home/20190829005017/en/

إنّ نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

Contacts

ميغان تسوي

"أندرسن تاكس"

هاتف: 4157642700

الرابط الثابت : https://www.aetoswire.com/ar/news/أندرسن-جلوبال-توسع-عملياتها-إلى-الدولة-ال-15-في-إفريقيا/ar

Andersen Global Expands Into 15th Country in Africa

SAN FRANCISCO-Friday 30 August 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Marking a milestone in its expansion into Africa, Andersen Global announced today it has entered into a collaboration agreement with ATax Advisors Limited (ATax), a leading tax and advisory firm in Mauritius, the 15th country in Africa in which the global organization now has a presence.

Based on the eastern African island nation of Mauritius, ATax has provided clients with a range of accounting, tax, payroll, outsourcing and business advisory services for the past 15 years. The firm serves international clients with needs around the globe with specific expertise serving African and Asian clients, as the country of Mauritius is commonly known as the gateway into India and Asia as well as Africa.

Ben Lim, one of the founders of ATax, and his team have intensive industry experience in a broad range of industries, including manufacturing and textile apparel, real estate construction and renovation, medical and pharmaceutical, automobile and motor vehicle spare parts, agriculture and farming, wholesale and retail on consumer goods, hospitality and tourism, education, BPO, customs brokerage and freight forwarding, jewelry, gambling, restaurants, retail and event management. The Mauritius team has extensive experience in cross border tax planning. ATax is also a member of the Mauritius Institute of Public Accountants.

“We have spent much time and effort crafting a business with a focus on providing best-in-class service and treating clients like they are our own family. Because of those simple values and endeavors, we have been able to grow in stature and reputation,” said Ben. “We are looking forward to this next step for our firm and collaborating with a group of likeminded colleagues throughout the world.”

“The ATax professionals are a premier team in Mauritius and there are many opportunities with this collaboration. Ben has roots in the Andersen family, and because of that, values such as transparency, seamlessness and stewardship run deep,” said Mark Vorsatz, Andersen Global Chairman and Andersen Tax LLC CEO. “Our momentum in the region is growing, and we will have the very best anchoring us in this important market in Africa.”

Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 4,500 professionals worldwide and a presence in over 148 locations through its member firms and collaborating firms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190829005017/en/

Contacts

Megan Tsuei
Andersen Tax
415-764-2700

Permalink : https://www.aetoswire.com/news/andersen-global-expands-into-15thnbspcountry-in-africa/en

Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients

• 10 years ago, RE-LY® marked the first time a randomised trial showed that a non-vitamin K

antagonist oral anticoagulant (NOAC) was safer and at least as effective as warfarin for stroke prevention in atrial fibrillation (SPAF) 1-3 

• First major scientific advancement in anticoagulation care in over fifty years

• Over 100,000 patients have been included in the RE-VOLUTION study programme worldwide, 1 and research into dabigatran etexilate continues

INGELHEIM, Germany-Friday 30 August 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication1-3 recognising the contribution made in the decade since by patients, healthcare professionals (HCPs) and researchers.

In the fifty years prior, warfarin had been the standard of care for stroke prevention in atrial fibrillation (SPAF). While effective, warfarin has a number of known interactions, meaning patients require careful monitoring, and the warfarin dose being adjusted accordingly. The pivotal RE-LY® trial investigated the efficacy and safety in stroke prevention of dabigatran compared to warfarin in 18,113 atrial fibrillation (AF) patients. It marked the first time that a non-vitamin K antagonist oral anticoagulant (NOAC), that has since been brought to market, was shown to be at least as effective and safer than warfarin in stroke prevention in a randomised setting.1-3 This represented the first puzzle piece in the growing knowledge base around NOACs as an alternative therapy option to vitamin K antagonists (VKAs) for SPAF.

“RE-LY® was the first crucial sign that a new, safer therapy option for SPAF was on its way,” said Stuart J. Connolly, MD, Professor Emeritus, Division of Cardiology at McMaster University in Hamilton, Ontario. “The positive results brought a real sense of excitement to researchers, HCPs and patients alike, and the subsequent approval of dabigatran for SPAF from 2010 onwards provided a safer, effective and more manageable therapy option. AF patients now had greater reassurance around stroke prevention and without the impact that regular monitoring and dose adjustment had on their day-to-day life.”

RE-LY® was just the start of the journey. The design, evaluation and subsequent approval of the first and only widely-available specific reversal agent (idarucizumab) in 2015 added to the bigger picture of understanding and reassured patients that the effects of dabigatran could be quickly and effectively reversed for emergency surgery / urgent procedures and in life-threatening or uncontrolled bleeding.5,6

“Today, Boehringer Ingelheim continues to deliver on its commitment to patients with high unmet need in the cardiovascular space and beyond,” said Dr Waheed Jamal, Corporate Vice President, Head of CardioMetabolic Medicine, Boehringer Ingelheim. “Thank you to the patients, HCPs and researchers who have helped and continue to help develop and expand access to safer and innovative therapies that improve the care of patients with a range of cardiometabolic conditions.”

About Stroke Prevention in Atrial Fibrillation (SPAF)

AF is the most common sustained heart rhythm condition.7 It can lead to a five-fold increase in the risk of ischaemic stroke for the 33.5 million people living with AF around the world.8,9 15 million people worldwide suffer a stroke each year. One–third of these people die as a consequence.10

About RE-LY®

The RE-LY® trial, which was published in the New England Journal of Medicine in September 2009, compared dabigatran to warfarin for preventing stroke in patients with AF.1-3 In the RE-LY® trial, 18,113 patients with non-valvular atrial fibrillation and a risk of stroke were investigated, using a PROBE (prospective, randomised, open label with blinded endpoint evaluation) design to assess the safety and efficacy of dabigatran 150mg or 110mg twice daily vs. dose-adjusted warfarin.11

Trial results demonstrated that dabigatran had notable advantages over warfarin even when warfarin is well controlled.1-3 Compared to warfarin:

Dabigatran 150mg twice daily was superior for the prevention of stroke / SE and significantly reduced the risk of both ischaemic and haemorrhagic stroke1-3,11

Rates of the primary outcome were 1.12% per year in the group that received 150mg of dabigatran (relative risk, 0.65; 95% CI, 0.52 to 0.81; P<0.001)

Rates of the primary outcome were 1.72% per year in the warfarin group, as compared with 1.54% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.89; 95% confidence interval [CI], 0.73 to 1.09; P=0.89) 1-3,12

Dabigatran significantly reduced the risk of intracranial haemorrhage (ICH), along with significant reductions in the risk of both life threatening and total bleeding1-3,12

The rate of major bleeding was 3.61% per year in the warfarin group, as compared with 2.92% per year in the group receiving 110 mg of dabigatran (P=0.003)1-3,12

The rate of major bleeding was 3.40% per year in the group receiving 150 mg of dabigatran (P=0.41)

About Pradaxa® (dabigatran etexilate)

Clinical experience of Pradaxa® equates to over 10 million patient-years in all licensed indications worldwide. Pradaxa® has been in the market for more than eight years and is approved in over 100 countries.4

Currently approved indications for Pradaxa® are:5,6

Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and a risk factor for stroke

Primary prevention of venous thromboembolic events in patients undergoing elective total hip replacement surgery or total knee replacement surgery

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and recurrent PE in adults

Dabigatran, a direct thrombin inhibitor (DTI), was the first widely approved drug in a new generation of direct oral anticoagulants, available to target a high unmet medical need in the prevention and treatment of acute and chronic thromboembolic diseases.13-15 Potent antithrombotic effects are achieved with direct thrombin inhibitors by specifically blocking the activity of thrombin, the central enzyme in the process responsible for clot (thrombus) formation.15 In contrast to vitamin K antagonists, which variably act via different coagulation factors, dabigatran provides effective, predictable and reproducible anticoagulation with a low potential for drug-drug interactions and no drug-food interactions, without the need for routine coagulation monitoring or mandatory dose adjustment.4,12

Pradaxa® is the only non-vitamin K antagonist oral anticoagulant with an approved, widely available reversal agent. Praxbind® is approved in the European Union and United States for adult patients treated with Pradaxa® who require rapid reversal of its anticoagulant effects prior to urgent procedures/emergency surgery or in life threatening or uncontrolled bleeding.5,6

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/re-ly-trial-publication-10-year-anniversary

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190830005071/en/

Contacts

Media Contact 

Boehringer Ingelheim 

Corporate Communications 

Media + PR 

Meike Bausinger 

Phone: +49 6132 77 182085 

Mobile: +49 151 44061760 

Fax: +49 6132 77 6601 

Email: press@boehringer-ingelheim.com

Permalink : https://www.aetoswire.com/news/anniversary-of-the-pivotal-re-lyregnbsptrial-marks-a-decade-of-innovation-for-stroke-prevention-in-af-patients/en